Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533761 · ClinicalTrials.gov registry record · Phase 1
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
A Phase 1 study of MDS and AML, Adult, sponsored by Stelexis BioSciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 13
- Study locations
NCT06533761 is a Phase 1 study of MDS and AML, Adult that is actively recruiting participants, run by Stelexis BioSciences. The registered enrollment target is 125 participants, above the 91-participant average among 22 other MDS trials with a reported enrollment target (37% higher). The trial reports 13 study locations across 9 states.
The verdict
NCT06533761, a Phase 1 study of MDS and AML, Adult, is actively recruiting participants, sponsored by Stelexis BioSciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination. * Part 2: Dose Optimization
Conditions Studied
Interventions
- DRUG Eganelisib
- DRUG Eganelisib in combination with cytarabine
Study Locations (13)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Other
- Hospital San Pedro de Alcántara - Cáceres
- Hospital Universitari i Politècnic La Fe - Valencia
California
- City of Hope - Duarte
Colorado
- Anshutz Cancer Pavilion - Aurora
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University in St Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2028-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06533761
The ClinicalTrials.gov registry entry for NCT06533761 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 22 other MDS trials with a reported enrollment target (37% higher). The listed sponsor is Stelexis BioSciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with MDS appearing as the primary indexed condition, and to 2 interventions - of which Eganelisib is the first listed.
NCT06533761 reports 13 study locations spanning 9 distinct geographic areas - top geographies include New York, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT06533761 about?
NCT06533761 is a clinical study titled "Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML". This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refra...
What is the current status of trial NCT06533761?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2025-04-28. Estimated completion is 2028-03-15.
What conditions does trial NCT06533761 study?
This clinical trial studies the following conditions: MDS, AML, Adult.
What interventions are being tested in trial NCT06533761?
The interventions under investigation include: Eganelisib (DRUG), Eganelisib in combination with cytarabine (DRUG).
Who is sponsoring clinical trial NCT06533761?
This trial is sponsored by Stelexis BioSciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533761 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.